Corgentech Announces Appointment of K. Peony Yu as Vice President, Clinical Research and Michael Leong as Director, Clinical Re
06 6월 2006 - 9:00PM
PR Newswire (US)
SOUTH SAN FRANCISCO, Calif., June 6 /PRNewswire-FirstCall/ --
Corgentech Inc. (NASDAQ:CGTK) today announced the appointment of K.
Peony Yu, M.D., as vice president of clinical research and Michael
Leong, M.D., as director of clinical research. Drs. Yu and Leong
have substantial experience in guiding pain drugs through clinical
trials and will play a key role in continued development of the
company's growing portfolio of drugs targeted at pain management.
"Dr. Yu and Dr. Leong have extensive experience in clinical
development of drugs targeted at pain, and also bring to the
company years of first-hand patient experience in pain management
practices," said John P. McLaughlin, chief executive officer of
Corgentech. "Corgentech is fortunate to have the opportunity to
leverage their knowledge to ensure the continued success and growth
of our clinical development program." Prior to joining Corgentech,
Dr. Yu worked at ALZA Corporation, a Johnson & Johnson company,
as a director of clinical development. There, she served as
IONSYS(TM) global clinical team leader and contributed to the
recent FDA approval and marketing authorization in the European
Union of IONSYS(TM) for the management of acute post-operative
pain. She also contributed to the in-licensing of pain products and
new product concepts as well as assisted in the submission of a new
drug application (NDA) for a urology product. Before ALZA, Dr. Yu
was a director of clinical development at Pain Therapeutics, Inc.
responsible for the clinical development program for Remoxy(TM) and
OxyTrex(TM), both for the management of moderate to severe chronic
pain, and an assistant director of clinical affairs at Elan
Pharmaceuticals where she contributed to the development of
PRIALT(R), which was subsequently approved by the FDA and European
commission for the management of severe chronic pain. She also had
nearly a decade of clinical experience at the Palo Alto Medical
Foundation, a 160-physician multi-specialty group, where she
founded the group's physical medicine and rehabilitation department
and co-founded the group's pain management service. Dr. Yu, who
received her medical degree from the University of California-Davis
and completed a residency at Stanford University School of
Medicine, is board certified by both the American Board of Physical
Medicine and Rehabilitation and the American Board of Pain
Medicine. Prior to joining Corgentech, Dr. Leong was a medical
director at Solstice Neuroscience Inc., the maker of Myobloc
(Botulinum Toxin type B). At Solstice, he oversaw the
implementation and operations of both sponsored and
investigator-driven clinical trials, in addition to providing input
on clinical development plans and medical education programs.
Before joining Solstice, Dr. Leong worked as an assistant professor
at the Stanford Pain Management Center for many years and continues
to teach as an adjunct assistant professor. He has also directed a
private practice clinical research center and was the primary
investigator for trials of novel topical and intrathecal
analgesics. In addition, Dr. Leong has published numerous articles
on pain management and has made data presentations both nationally
and internationally. Dr. Leong received his medical degree from
Georgetown University Medical School and completed his residency
and a fellowship at Stanford University School of Medicine. He is
board certified in anesthesiology with a sub-specialty in pain
management. About Corgentech Corgentech is a late-stage
biopharmaceutical company that seeks to be the leader in the
development and commercialization of novel therapeutic treatments
for pain. The company has four drug candidates in clinical
development for multiple potential indications, the most advanced
of which, 3268, has completed Phase 3 clinical trials. To reflect
the company's core focus on novel pain management therapies, the
board of directors recently voted to change the company name to
Anesiva. If approved by stockholders at the annual meeting on June
21, 2006, the name change will become effective immediately
thereafter. Corgentech is based in South San Francisco, CA. Forward
Looking Statements This press release includes "forward-looking
statements" within the meaning of the safe harbor provisions of the
United States Private Securities Litigation Reform Act of 1995.
Words such as "expect," "estimate," "project," "budget,"
"forecast," "anticipate," "intend," "plan," "may," "will," "could,"
"should," "believes," "predicts," "potential," "continue," and
similar expressions are intended to identify such forward-looking
statements. Forward-looking statements in this press release
include, without limitation, projected timing of clinical
development and other matters that involve known and unknown risks,
uncertainties and other factors that may cause actual results,
levels of activity, performance or achievements to differ
materially from results expressed or implied by this press release.
Such risk factors include, among others: whether Corgentech can
successfully develop new products and the degree to which these
gain market acceptance. Actual results may differ materially from
those contained in the forward-looking statements in this press
release. Additional information concerning these and other risk
factors is contained in Corgentech's quarterly report on Form 10-Q
for the quarter ended March 31, 2006. Corgentech undertakes no
obligation and does not intend to update these forward-looking
statements to reflect events or circumstances occurring after this
press release. You are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
of this press release. All forward-looking statements are qualified
in their entirety by this cautionary statement. DATASOURCE:
Corgentech Inc. CONTACT: Jennifer Cook Williams, Vice President,
Investor Relations, +1-650-624-9600, or Web site:
http://www.corgentech.com/
Copyright
Corgentech (NASDAQ:CGTK)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
Corgentech (NASDAQ:CGTK)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024